Protekt Therapeutics is a biopharmaceutical company aiming to identify and develop a potent and selective oral PKR inhibitor (PKRi) to treat cognitive disorders such as Alzheimers disease and mild cognitive impairment.

PKR is a stress and proapoptotic kinase that phosphorylates eIF2, a key protein in the translation machinery, and results in inhibition of protein synthesis and impaired memory consolidation.PKR is also activated during apoptosis, autophagy, neuroinflammation, and A peptide toxicity, which are prominent features of Alzheimers Disease (AD).

Therefore, PKR inhibition offers a novel and promising disease-modifying mechanism for modulating multiple key processes in AD and other neurodegenerative diseases.Protekt Therapeutics was established in the FutuRx Incubator in December 2015.